Australia markets closed
  • ALL ORDS

    6,784.30
    -33.80 (-0.50%)
     
  • AUD/USD

    0.6802
    +0.0003 (+0.04%)
     
  • ASX 200

    6,594.50
    -34.80 (-0.52%)
     
  • OIL

    99.76
    +0.26 (+0.26%)
     
  • GOLD

    1,760.20
    -3.70 (-0.21%)
     
  • BTC-AUD

    29,579.23
    +370.66 (+1.27%)
     
  • CMC Crypto 200

    436.24
    -3.79 (-0.86%)
     

Establishment Labs to Announce First Quarter 2022 Financial Results on May 9

  • Oops!
    Something went wrong.
    Please try again later.
·2-min read
In this article:
  • Oops!
    Something went wrong.
    Please try again later.

SANTA BARBARA, Calif., April 28, 2022--(BUSINESS WIRE)--Establishment Labs Holdings Inc. (NASDAQ: ESTA), a global medical technology company dedicated to improving women’s health and wellness, principally in breast aesthetics and reconstruction, plans to announce its financial results for the quarter ended March 31, 2022 after the market closes on Monday, May 9, 2022, and will host a conference call at 4:30 pm ET that day to discuss those results.

To participate in the conference call, dial (877) 407-8037 (U.S. and Canada) or (201) 689-8037 (International) and use conference ID number 13729225. The call will also be available via live or archived webcast on the "Investor Relations" section of the Establishment Labs website at www.establishmentlabs.com.

About Establishment Labs

Establishment Labs Holdings Inc. is a global medical technology company dedicated to improving women’s health and wellness. The company’s initial focus is breast health, principally breast aesthetics and reconstruction. Establishment Labs offers a portfolio of advanced silicone gel-filled breast implants, branded as Motiva Implants® that include a number of innovative and patented features designed to deliver improved aesthetic and clinical outcomes. Since commercial launch in 2010, more than 2.0 million Motiva Implants® have been delivered to plastic surgeons in over 80 countries. The company also offers or has under development a number of related products and technologies, including the Motiva Flora® tissue expander and Motiva MIA®, the company’s minimally invasive breast enhancement procedure. In 2018, Establishment Labs received an investigational device exemption (IDE) from the FDA for the Motiva Implant® and began a clinical trial to support regulatory approval in the United States. Motiva Implants® are manufactured at the company’s two facilities in Costa Rica, which are compliant with all applicable regulatory standards under ISO13485:2016 and FDA 21 CFR 820 under the MDSAP program. Please visit our website for additional information at www.establishmentlabs.com.

View source version on businesswire.com: https://www.businesswire.com/news/home/20220428005164/en/

Contacts

Investor/Media Contact:
Raj Denhoy
415-828-1044
Rdenhoy@establishmentlabs.com

Our goal is to create a safe and engaging place for users to connect over interests and passions. In order to improve our community experience, we are temporarily suspending article commenting